|
Jul 17
|
Ligand Pharmaceuticals Stock Earns 84 RS Rating
|
|
Jul 16
|
3 Stocks That Might Be Undervalued And Present An Investment Opportunity
|
|
Jul 16
|
First Solar And 2 Additional Stocks That May Be Priced Below Estimated Value
|
|
Jul 14
|
3 Stocks That May Be Trading Below Estimated Value In July 2025
|
|
Jul 14
|
3 Stocks Estimated To Be Trading At A Discount Of Up To 25.8%
|
|
Jun 17
|
Incyte And Two Other Stocks That May Be Priced Below Their Estimated Value
|
|
May 14
|
Ligand to Ring the Nasdaq Opening Bell on May 19, 2025
|
|
May 12
|
LGND: 1Q:25 Results
|
|
May 11
|
Ligand Pharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Feb 13
|
Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
|
|
Oct 9
|
Ligand Pharmaceuticals Inc (LGND) Q2 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...
|
|
Oct 9
|
LGND: Initiating Coverage – A Prince Among Royalty
|
|
Jul 23
|
Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024
|
|
Jun 14
|
Shattuck (STTK) Announces Positive Interim Data on Cancer Drug
|
|
Jun 14
|
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro
|
|
Jun 14
|
What Makes Ligand (LGND) a New Strong Buy Stock
|
|
May 23
|
Ligand to Participate in Upcoming Investor Conferences
|
|
May 21
|
AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030
|
|
May 21
|
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
|
|
May 21
|
PTC Therapeutics (PTCT) Up as EC Returns CHMP Opinion on DMD Drug
|